EFNB2 (Ab-330) Antibody

What is EFNB2 (Ab-330) Antibody and what epitope does it recognize?

EFNB2 (Ab-330) Antibody is a rabbit polyclonal antibody that specifically recognizes endogenous levels of total Ephrin-B2 protein. It was generated using a synthetic peptide corresponding to amino acids 328-332 (N-I-Y-Y-K) derived from human Ephrin-B2 . The antibody was produced by immunizing rabbits with this peptide conjugated to KLH (keyhole limpet hemocyanin) as a carrier protein and subsequently purified through affinity chromatography using the epitope-specific peptide . The target protein, Ephrin-B2, is a membrane-bound ligand that plays crucial roles in various developmental processes and also serves as a cellular receptor for certain viruses including Nipah and Hendra viruses .

What applications is EFNB2 (Ab-330) Antibody validated for?

The EFNB2 (Ab-330) Antibody has been validated for multiple research applications:

The antibody has demonstrated specificity in detecting Ephrin-B2 across multiple species including human, mouse, and rat samples . For optimal results in Western blotting, researchers should ensure proper sample preparation and consider using recommended secondary antibodies such as goat anti-rabbit IgG conjugated to HRP, AP, FITC, or biotin depending on the detection method .

What are the optimal storage and handling conditions for EFNB2 (Ab-330) Antibody?

For optimal performance and longevity of the EFNB2 (Ab-330) Antibody, researchers should follow these storage guidelines:

• Long-term storage: -20°C (recommended for preservation of antibody activity)

• Short-term storage: 4°C (suitable for immediate use within a few weeks)

• Avoid repeated freeze-thaw cycles as this can degrade antibody performance

• The antibody is supplied at 1.0 mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, containing 150mM NaCl, 0.02% sodium azide, and 50% glycerol

The inclusion of glycerol prevents freezing at -20°C and helps maintain antibody stability. When handling, it's advisable to aliquot the antibody upon first thawing to minimize freeze-thaw cycles, which can lead to denaturation and loss of binding efficiency. Working dilutions should be prepared fresh before use for optimal experimental results.

How can specificity of EFNB2 (Ab-330) Antibody be validated in experimental settings?

To validate the specificity of EFNB2 (Ab-330) Antibody in your experimental system, consider implementing these approaches:

• Positive controls: Include lysates from cell lines known to express high levels of Ephrin-B2 (e.g., endothelial cells)

• Negative controls: Use tissues or cells with minimal or no Ephrin-B2 expression

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide (N-I-Y-Y-K sequence) to block specific binding

• siRNA knockdown validation: Compare staining in cells with and without EFNB2 knockdown

• Cross-reactivity testing: Test against related Ephrin family proteins to confirm specificity

When validating for virus-related studies, cells expressing tagged versions of EFNB2 can serve as additional controls. For instance, cells expressing EFNB2 with N-terminal c-myc tags have been used to verify surface expression in viral binding studies . This approach helps distinguish between antibody binding to EFNB2 versus potential non-specific interactions.

How can EFNB2 (Ab-330) Antibody be used to study henipavirus infection mechanisms?

EFNB2 (Ab-330) Antibody can be instrumental in studying henipavirus infection mechanisms through several advanced approaches:

• Receptor expression analysis: The antibody can quantify EFNB2 expression levels across different cell types to correlate with susceptibility to henipavirus infection. This helps identify target cells most vulnerable to viral entry.

• Conformational studies: Since EFNB2 undergoes conformational changes when engaging viral G glycoproteins versus Eph receptors, this antibody can help identify the native conformation recognized during viral binding. The antibody recognizes total EFNB2 protein regardless of conformation, making it useful for baseline expression studies .

• Competitive binding assays: Researchers can use EFNB2 (Ab-330) Antibody in competitive binding experiments to determine whether it interferes with binding of viral glycoproteins. This provides information about epitope accessibility during virus-receptor interactions.

• Viral attachment visualization: In conjunction with labeled viral particles, the antibody can be used in co-localization studies to visualize attachment sites on cellular membranes. Immunofluorescence techniques at the recommended dilution (1:100-1:200) can map the distribution of EFNB2 relative to viral attachment proteins .

• Mutation impact assessment: For studies examining EFNB2 mutations that affect henipavirus binding (such as the D62Q mutation identified in research), this antibody can verify that mutant proteins are properly expressed and localized before testing their virus-binding properties .

What methodological considerations are important when using EFNB2 (Ab-330) Antibody to study receptor-virus interactions?

When using EFNB2 (Ab-330) Antibody to investigate receptor-virus interactions, researchers should consider these methodological aspects:

How can EFNB2 (Ab-330) Antibody be used to validate engineered EFNB2 variants designed for therapeutic applications?

EFNB2 (Ab-330) Antibody can play a crucial role in validating engineered EFNB2 variants being developed as potential henipavirus therapeutics through these approaches:

What approaches can be used with EFNB2 (Ab-330) Antibody to study the G-H binding loop conformations in EFNB2?

The G-H binding loop of EFNB2 undergoes significant conformational changes when binding to different partners, and EFNB2 (Ab-330) Antibody can be utilized in several sophisticated approaches to study these dynamics:

• Competitive binding analysis: Using the antibody in combination with either soluble NiV-G or EphB receptors can reveal whether the Ab-330 epitope accessibility changes during binding events. This provides indirect evidence of conformational shifts in the G-H loop region.

• Protection/sensitivity assays: This methodology involves:

  • Pre-binding EFNB2 with either viral G proteins or Eph receptors

  • Testing whether this binding protects or exposes the Ab-330 epitope

  • Comparing binding efficiency to free EFNB2

  • Inferring conformational changes based on altered antibody accessibility

• Mutation impact assessment: For EFNB2 variants with mutations at the "phenylalanine hinge" upon which the G-H loop pivots (as described in the research), the antibody can verify equivalent expression levels when comparing binding preferences . This controls for expression variability when analyzing conformational selectivity.

• Cross-linking studies: When combined with chemical cross-linking approaches, the antibody can help identify whether the Ab-330 epitope becomes more or less accessible after stabilizing EFNB2 in specific conformations through cross-linking to binding partners.

• Co-immunoprecipitation assays: The antibody can be used in pull-down experiments to determine whether EFNB2 bound to different partners (viral G proteins versus Eph receptors) is equally detectable, providing information about epitope accessibility in different bound states.

How can EFNB2 (Ab-330) Antibody contribute to studies developing henipavirus therapeutics?

EFNB2 (Ab-330) Antibody can significantly contribute to developing potential henipavirus therapeutics through several research applications:

• Screening soluble EFNB2 variants: Research has shown that soluble EFNB2-Fc fusion proteins can neutralize henipaviruses, including NiV and HeV . The antibody can confirm the identity and integrity of these decoy receptors during manufacturing and quality control.

• Validating EFNB2 specificity mutations: Studies have identified specific mutations like D62Q that enhance EFNB2 specificity for henipavirus G proteins while reducing binding to Eph receptors . The antibody can verify that these engineered proteins maintain structural integrity while exhibiting altered binding profiles.

• Assessing receptor competition: In therapeutic development efforts focusing on blocking virus-receptor interactions, the antibody can help quantify how effectively candidate molecules compete with cellular EFNB2 for virus binding.

• Evaluating cross-reactive potential: For newly discovered henipavirus variants like HeV-g2, the antibody can help determine whether EFNB2 recognition is conserved across strains, informing the development of broadly effective therapeutics .

• Monitoring in vivo biodistribution: When developing EFNB2-based therapeutics, the antibody can be used to track the biodistribution and persistence of these agents in animal models, helping optimize dosing and administration routes.

Future Research Directions

Emerging research directions where EFNB2 (Ab-330) Antibody may prove particularly valuable include:

• Investigation of newly discovered henipavirus variants and their interaction with EFNB2

• Development and validation of engineered EFNB2 variants with enhanced therapeutic potential

• Structural studies examining conformational changes in EFNB2 during different binding events

• High-throughput screening of compounds that modulate EFNB2-virus interactions

• In vivo tracking of EFNB2-expressing cells during viral infection and disease progression